- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.11. | Vaccine-focused Valneva consolidates R&D footprint by shuttering site, eliminating 30 roles | ||
| 26.11. | AI may be the key to reigniting VC interest in biotech: PitchBook | ||
| 26.11. | FDA delays decision on Ascendis' dwarfism prospect by 3 months | ||
| 25.11. | US commission recommends federal research revamp to avoid losing global biotech edge | ||
| 25.11. | AbbVie launches lab space award program for Quebec biotechs | ||
| 25.11. | Novo Nordisk expands pivotal amycretin program after dual agonist shines in diabetes | ||
| 24.11. | Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone | ||
| 24.11. | Gilead hatches $400M biobucks deal for Swedish biotech's TREX1 cancer program | ||
| 24.11. | Versant's Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission | ||
| 24.11. | J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2 | ||
| 24.11. | Bayer's asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class | ||
| 21.11. | In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation | ||
| 21.11. | FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process | ||
| 20.11. | Moderna's reshaping rolls on with 3 more pipeline purges | ||
| 20.11. | Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3 | ||
| 20.11. | Ensoma halves workforce after transitioning genetic medicine to the clinic | ||
| 20.11. | Applied Tx lays off 46% of workforce as rare disease drug approval looks out of reach | ||
| 20.11. | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| 19.11. | Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO | ||
| 19.11. | Celltrion still thinking bigger than biosimilars with option for $350M antibody deal | ||
| 19.11. | Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir | ||
| 19.11. | Gilead wants us to 'rebuild': Why Galapagos isn't allowed to go extinct after turbulent year | ||
| 19.11. | GSK pens $50M LTZ pact to join Big Pharma peers in emerging myeloid cell engager space | ||
| 18.11. | How Biogen is returning to its roots with a West Coast immunology outpost | ||
| 18.11. | Vanda tackles Wegovy-driven vomiting, sparking race to phase 3 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .